Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer—A Review

Süveg, Krisztian; Plaßwilm, Ludwig; Iseli, Thomas; Leskow, Pawel; Fischer, Galina Farina; Putora, Paul Martin

doi:10.3390/cancers14071617

Cited by 8 publications

(5 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the end of concurrent chemoradiotherapy, PD-L1 inhibitors can also be used for immunoconsolidation therapy. [61,64,65] Systemic treatment for stage IV lung cancer is the main means, advanced patients should receive genetic testing, targeted therapy is better than chemotherapy. Patients who do not have the gene mutation may choose immunotherapy and/or chemotherapy.…”

Section: The Role Of Immunotherapy In the Clinical Treatment Of Lung ...mentioning

confidence: 99%

The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy

Wang,

Gao,

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

The lungs are the largest surface of the body and the most important organ in the respiratory system, which are constantly exposed to the external environment. Tissue Resident Macrophages in lung constitutes the important defense against external pathogens. Macrophages connects the innate and adaptive immune system, and also plays important roles in carcinogenesis and cancer immunotherapy. Lung cancer is the leading cause of cancer‐related death worldwide, with an overall five‐year survival rate of only 21%. Macrophages that infiltrate or aggregate in lung tumor microenvironment are defined as tumor‐associated macrophages (TAMs). TAMs are the main components of immune cells in the lung tumor microenvironment. The differentiation and maturation process of TAMs can be roughly divided into two different types: classical activation pathway produces M1 tumor‐associated macrophages, and bypass activation pathway produces M2 tumor‐associated macrophages. Studies have found that TAMs are related to tumor invasion, metastasis, and treatment resistance, and show potential as a new target for tumor immunotherapy. Therefore, the biological function of macrophages in lung and the role of TAMs in the occurrence, development, and treatment of lung cancer are discussed in this paper.

show abstract

Section: The Role Of Immunotherapy In the Clinical Treatment Of Lung ...mentioning

confidence: 99%

The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy

Wang,

Gao,

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

show abstract

“…Moreover, if patients are to undergo an additional adjuvant treatment, the risk for radiotherapy-related pneumonitis can increase. More recent radiotherapy techniques such as, 3D conformal radiation therapy (3D-CRT), IMRT or volumetric modulated arc therapy (VMAT) showed potential benefits while reducing the risks of radiotherapy-related toxicities [35][36][37][38] .…”

Section: Safety Issuesmentioning

confidence: 99%

Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

Lim

2023

Tuberc Respir Dis

View full text Add to dashboard Cite

Significant proportion of patients with non-small cell lung cancer (NSCLC) are diagnosed in early and resectable stage. Despite use of platinum-based adjuvant chemotherapy, there was only marginal increase in overall survival, and 15% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained.

show abstract

“…PORT in stage IIIA-N2 NSCLC is a treatment approach that raises concerns regarding the occurrence of toxicities, particularly cardiopulmonary toxicity. Studies have shown that excessive radiation volumes, suboptimal radiation techniques, large doses and fraction sizes, and noncomputed tomography (CT)-based treatment planning contribute to increased toxicity and noncancer-related deaths associated with PORT [20].…”

Section: Port Toxicitymentioning

confidence: 99%

Is there role of adjuvant radiotherapy after complete resection of locally advanced nonsmall cell lung cancer?

Jiang,

Meng

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review This review aims to provide a timely and relevant overview of the role of postoperative radiotherapy (PORT) in completely resected stage IIIA-N2 nonsmall cell lung cancer (NSCLC). Given the controversy surrounding the use of PORT and the emergence of advanced radiation techniques and therapies, this review provides valuable insight into current and potential treatment strategies. Recent findings The Lung ART and PORT-C trials have provided valuable insights into the efficacy of PORT in stage IIIA-N2 NSCLC. While the results have been mixed, studies have shown that advanced radiation techniques, such as intensity-modulated radiotherapy (IMRT) and proton therapy, can reduce cardiopulmonary toxicities associated with PORT. Molecular targeted therapies and immunotherapies have also shown potential in improving NSCLC treatment outcomes. Summary The role of radiotherapy becomes smaller and smaller in new era. However, it is too early to abolish radiotherapy for all the patients after complete resection of locally advanced NSCLC. Nowadays, it is recommended to adopt individualized treatment approaches guided by multidisciplinary team consultations. The integration of IMRT, proton therapy, and emerging therapies offers the potential to enhance treatment efficacy while minimizing toxicity. Further research is needed to optimize the use of PORT and explore the method to identify the patients who can really benefit from PORT.

show abstract

Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer—A Review

Cited by 8 publications

References 82 publications

The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy

The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy

Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

Is there role of adjuvant radiotherapy after complete resection of locally advanced nonsmall cell lung cancer?

Contact Info

Product

Resources

About